Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation

Pharmacology

Volumn 90, Issue 3-4, 2012, Pages 223-232

  Kobayashi, Miki ^a   Kubo, Satoshi ^a   Shiraki, Katsuhisa ^b   Iwata, Masahiro ^a   Hirano, Yasuno ^a   Ohtsu, Yoshiaki ^a   Takahashi, Koichiro ^a   Shimizu, Yasuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Drug Safety Research Labs   (Japan)

Author keywords

Brown Norway rat; Emesis; Eosinophil; Fibrinogen; Phosphodiesterase 4; Vascular injury

Indexed keywords

ASP 3258; FIBRINOGEN; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; OVALBUMIN; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4C; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CHRONIC EOSINOPHILIC AIRWAY INFLAMMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; EOSINOPHIL; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IC 50; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RESPIRATORY TRACT INFLAMMATION; VOMITING;

ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CHRONIC DISEASE; EOSINOPHILIA; FEMALE; FIBRINOGEN; HUMANS; INTERLEUKIN-5; MALE; NAPHTHYRIDINES; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, INBRED BN; RATS, INBRED F344; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867191299     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342380     Document Type: Article

References (49)

1. Barnes PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 2003;14:511-522.
2. Donohue JF: Therapeutic responses in asthma and COPD. Bronchodilators. Chest 2004;126:125S-137S, discussion 159S-161S.
3. Global strategy for asthma management and prevention (GINA). http://www.ginasthma. org/guidelines-gina-report-globalstrategy-for-asthma.html (updated 2009).
4. Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905-1917.
5. Page CP, Spina D: Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012;12:275-286.
6. Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, Umetsu D, Conti M: Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010;126:1252-1259.e1212.
7. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC: Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;110:1045-1052.
8. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-171.
9. Souness JE, Aldous D, Sargent C: Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000;47: 127-162.
10. Spina D: Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-2594.
11. Souness JE, Rao S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997;9: 227-236.
12. Heaslip RJ, Evans DY: Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 1995;286: 281-290.
13. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH: Ariflo (SB 207499), a second generation phosphodiesterase inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-135.
14. Giembycz MA: Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:326-333, discussion 340-341.
15. Mecklenburg L, Heuser A, Juengling T, Kohler M, Foell R, Ockert D, Tuch K, Bode G: Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol Lett 2006;163:54-64.
16. Hanton G, Sobry C, Dagues N, Provost JP, Le Net JL, Comby P, Chevalier S: Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol Lett 2008;179: 15-22.
17. Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM: The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 2004;32:295-308.
18. Dagues N, Pawlowski V, Guigon G, Ledieu D, Sobry C, Hanton G, Freslon JL, Chevalier S: Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor. Toxicol Appl Pharmacol 2007;218:52-63.
19. Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y: Asp3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. Int Immunopharmacol 2011;11:732-739.
20. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-279.
21. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ: Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499. (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998;287:988-995.
22. Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, Shimizu Y: Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor. Int Immunopharmacol 2012;12:59-63.
23. Kubo S, Kobayashi M, Iwata M, Takahashi K, Miyata K, Shimizu Y: Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs. Eur J Pharmacol 2011;659: 79-84.
24. Kobayashi M, Kubo S, Hirano Y, Kobayashi S, Takahashi K, Shimizu Y: Anti-asthmatic effect of asp3258, a novel phosphodiesterase inhibitor. Int Immunopharmacol 2012;12: 50-58.
25. Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T: Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 2001;298: 1142-1149.
26. Ohga K, Kuromitsu S, Takezawa R, Numazaki M, Ishikawa J, Nagashima S, Shimizu Y: YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models. Eur J Pharmacol 2008;590:409-416.
27. Ohga K, Takezawa R, Arakida Y, Shimizu Y, Ishikawa J: Characterization of YM-58483/BTP2, a novel store-operated Ca2+ entry blocker, on T cell-mediated immune responses in vivo. Int Immunopharmacol 2008; 8:1787-1792.
28. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H: The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23:235-256.
29. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, Huang Z, Nicholson DW, Mancini JA: Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3, 4-bisdifluromethoxyphenyl)- 2-[4-(1,1, 1,3,3,3-hexafluoro-2-hydroxy propan-2-yl)-phenyl]-ethyl]3- methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310: 752-760.
30. Draheim R, Egerland U, Rundfeldt C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-gly oxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004;308:555-563.
31. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW: Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001;2: 71-79.
32. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
33. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC: Assessing the emetic potential of pde4 inhibitors in rats. Br J Pharmacol 2002;135:113-118.
34. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC: PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001;40:262-269.
35. Dietsch GN, Dipalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST: Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 2006;34:39-51.
36. Dagues N, Pawlowski V, Sobry C, Hanton G, Borde F, Soler S, Freslon JL, Chevalier S: Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol Sci 2007;100:238-247.
37. Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K, David M, Knoerzer D, Wurst W, Gleiter CH: Dose-proportional intraindividual single-and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007;47:26-36.
38. Sellers EM, Koch-Wester J: Albumin Structure, Function, and Uses. New York, Pergamon Press, 1997, pp 159-182.
39. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock CA, Woolcock AJ: Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000;16:226-235.
40. Bateman ED, Clark TJ, Frith L, Bousquet J, Busse WW, Pedersen SE: Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study. J Asthma 2007;44: 667-673.
41. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al: Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-1039.
42. Ikemura T, Schwarze J, Makela M, Kanehiro A, Joetham A, Ohmori K, Gelfand EW: Type phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther 2000;294:701-706.
43. Holgate ST, Djukanovic R, Casale T, Bousquet J: Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35: 408-416.
44. Giembycz MA: Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238-244.
45. Spina D: PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-315.
46. Larson JL, Pino MV, Geiger LE, Simeone CR: The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 1996;78:44-49.
47. Robertson DG, Reily MD, Albassam M, Dethloff LA: Metabonomic assessment of vasculitis in rats. Cardiovasc Toxicol 2001;1: 7-19.
48. Slim RM, Robertson DG, Albassam M, Reily MD, Robosky L, Dethloff LA: Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol Appl Pharmacol 2002;183:108-109.
49. Slim RM, Song Y, Albassam M, Dethloff LA: Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol Pathol 2003; 31:638-645.